The Metabolic Syndrome
|
|
- Edith Miller
- 6 years ago
- Views:
Transcription
1 The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C, high triglycerides, increased remnant lipoproteins, small LDL and HDL particles elevated blood pressure insulin resistance glucose intolerance type II diabetes proinflammatory state increased CRP prothrombotic state increased fibrinogen and PAI-1 Grundy et al, Circulation 24;19:433 Criteria for Clinical Identification of the Metabolic Syndrome According to ATP III Factors That Contribute to the Metabolic Syndrome 1. waist circumference >4 inches for men or 35 inches for women 2. triglycerides 15 mg/dl 3. HDL-C <4 mg/dl for men or <5 mg/dl for women 4. BP 13/ 85 mm Hg 5. fasting glucose 11 mg/dl 3 of 5 required for diagnosis Adapted from Kahn R, Circulation 27;115:186 Truncal Obesity Is a Key Component of the Metabolic Syndrome Insulin sensitive Insulin resistant Sironi AM et al, Hypertension 24;44:127 Mediastinal and Abdominal Fat Is Related to Hypertension and Insulin Resistance 13 hypertensives compared to 26 age and BMI-matched men intra-abdominal and intrathoracic fat measured by MRI intra-abdominal and intrathoracic fat was significantly greater in hypertensives insulin sensitivity was and total insulin output in hypertensives Conclusion: visceral adiposity is related to both height of BP and insulin resistance
2 Impact of the Metabolic Syndrome on Coronary Heart Disease Mortality in US Adults Clinical Management of the Metabolic Syndrome Prospective cohort study of 6255 subjects aged 3-75 from NHANES II Followed for a mean of 13 years Adjusted hazard ratio for CHD mortality in metabolic syndrome was 2. (95% CI ) Those with even 1-2 risk factors for metabolic syndrome had increased CHD mortality Deaths/1, Person Years No MS or DM MS only MS + DM DM only CVD CVD + DM CHD Mortality The underlying risk factors that promote development of the metabolic syndrome are overweight and obesity, physical inactivity, and an atherogenic diet. All current guidelines on the management of the individual components of the metabolic syndrome emphasize that lifestyle modification (weight loss and physical activity) is first-line therapy. Grundy et al, Circulation 24;19:551 Malik et al, Circulation 24;11:1245 Obesity Trends* Among U.S. Adults BRFSS, 199 (*BMI 3, or ~ 3 lbs overweight for 5 4 person) Obesity Trends* Among U.S. Adults BRFSS, 1992 (*BMI 3, or ~ 3 lbs overweight for 5 4 person) No Data <1% 1% 14% No Data <1% 1% 14% 15% 19% Obesity Trends* Among U.S. Adults BRFSS, 1994 (*BMI 3, or ~ 3 lbs overweight for 5 4 person) Obesity Trends* Among U.S. Adults BRFSS, 1996 (*BMI 3, or ~ 3 lbs overweight for 5 4 person) No Data <1% 1% 14% 15% 19% No Data <1% 1% 14% 15% 19%
3 Obesity Trends* Among U.S. Adults BRFSS, 1998 (*BMI 3, or ~ 3 lbs overweight for 5 4 person) Obesity Trends* Among U.S. Adults BRFSS, 2 (*BMI 3, or ~ 3 lbs overweight for 5 4 person) No Data <1% 1% 14% 15% 19% 2% No Data <1% 1% 14% 15% 19% 2%
4 Diabetes Trends* Among Adults in the U.S., (Includes Gestational Diabetes) BRFSS, 199,1995 and No Data <4% 4%-6% 6%-8% 8%-1% >1% Source: Mokdad et al., Diabetes Care 2;23: ; J Am Med Assoc 21;286:1. Portion Sizes Are Enormous High-powered ambulance chaser, Milford Godfrey, Manhattan, New York, snacks on a full-size rotisserie chicken while conducting business on his cell phone. He keeps a Rotisserie basting oven in his Lincoln Navigator and a George Foreman Grill in his brief case to squeeze in feedings between malpractice trials.
5 Lack of Physical Activity Does Urban Sprawl Contribute to Obesity? A typical white male living in an isolated residential only neighborhood weighs about 1 pounds more than one living in a walkable, mixed-use community. Lawrence Frank, 24 Densely built urban areas such as Vancouver s downtown may encourage pedestrian traffic and promote physical activity. Metropolitan Atlanta, often called a poster child for urban sprawl, has undergone rapid geographical expansion. Harder B, Science News Online, 27;171:43 Age: 44 years Weight: 26 lbs Height: 5 4 BMI: 35.4 BP: 142/88 mmhg Fasting blood sugar 116 mg/dl Total C: 24 mg/dl HDL-C: 36 mg/dl Triglycerides: 42 mg/dl LDL-C: 134 mg/dl hs-crp: 2.6 mg/dl Non-smoker What Is the 1-Year Risk of Cardiac Death or MI in This Patient According to Framingham? 2% 4% 6% 1% 14% 18% What Is the 1-Year Risk of Cardiac Death or MI in This Patient According to Framingham? 2% 4% 6% 1% 14% 18% 2% is the correct answer. However, the Framingham calculator does not count hs-crp, triglycerides or BMI, and does not include other coronary events or any cerebrovascular events in the endpoint. Effects of Diet and Exercise in Men and Postmenopausal Women with Low HDL-C 18 postmenopausal women aged with HDL-C <6 mg/dl and 197 men aged 3-64 with HDL-C <45 mg/dl randomized to NCEP step 2 diet, exercise (equivalent to 1 miles of jogging/walking per week), both, or neither interventions continued for 1 year mean baseline HDL-C was 47 mg/dl in women and 36 mg/dl in men; baseline LDL-C averaged 158 mg/dl Stefanick M et al, N Engl J Med 1998;339:12
6 Effects of Diet and Exercise in Women with Low HDL-C mg/dl p<.1 p=ns p=.3 Wt (kg) HDL-C LDL-C Control Exercise Diet D + E Prevention of Type 2 Diabetes by Lifestyle Changes Among Subjects with Impaired Glucose Tolerance 522 patients with impaired glucose tolerance (mean age 55, mean BMI 31) randomly assigned to weight reduction and exercise or to control group mean weight loss of 4.2 Kg in intervention group versus.8 Kg in control group at one year (p<.1) diabetes defined by 1985 WHO criteria cumulative incidence of diabetes at 4 years was 11% in the intervention group and 25% in the control group, a 58% reduction (p<.1) the reduction in the incidence of diabetes was directly associated with changes in lifestyle Stefanick M et al, N Engl J Med 1998;339:12 Tuomilehto et al, N Engl J Med 21;344:1343 Effect of Smoking Cessation on HDL-Cholesterol Levels meta-analysis of 27 studies from smoking cessation increased HDL-C by 1.8 mg/dl (95% CI ) increase greater in women and subjects with higher baseline HDL-C no change in total or LDL-cholesterol, or triglycerides Maeda et al, Prev Med 23;37:283 Relationship of Alcohol Intake to Change in HDL-C: a Meta-Analysis 36 data records from 25 studies on average, 41 g/day of alcohol increased HDL-C by 5.1 mg/dl 2 drinks (3 g of alcohol) will increase HDL-C by 4 mg/dl, or 8.3% 2 drinks will reduce the predicted risk of CHD by 24.7%, based on changes in biomarkers (fibrinogen, tpa, Lp(a), apo A1, etc) Rimm et al, BMJ 1999;319:1523 Potential Drug Therapy for Metabolic Syndrome fibrate niacin statin glitazone rimonabant antihypertensive aspirin Helsinki Heart Study 4,81 men with no evidence of coronary disease randomized to gemfibrozil 6 mg BID or placebo and followed for 5 years mean HDL-C increased from 47 to 52 mg/dl (1.2 to 1.3 mmol/l) and triglycerides decreased from 175 to 13 mg/dl ( 2. to 1.2 mmol/l); LDL-C decreased from 189 to 173 mg/dl (4.9 to 4.5 mmol/l) primary endpoint, cardiac death + nonfatal MI, reduced by 34%, from 84 to 56 (p=.2) Frick MH et al, N Engl J Med 1987;317:1237
7 Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) 2,531 men with coronary disease, an HDL-C 4 mg/dl and an LDL-C 14 mg/dl randomized to gemfibrozil 1,2 mg/day or placebo median follow-up = 5.1 years primary endpoint = coronary death + nonfatal MI HDL-C 6% higher and triglycerides 31% lower at 1 year in gemfibrozil group; no difference in LDL-C event rate 21.7% in placebo and 17.3% in gemfibrozil group, a 22% relative risk reduction (p=.6) Rubins et al, N Engl J Med 1999;341:41 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Trial 9,795 patients with type II diabetes randomized to micronized fenofibrate 2 mg/day or to placebo and followed for 5 years total cholesterol mmol/l with either a TC/HDL-C ratio 4 or triglycerides mmol/l primary outcome (coronary death or nonfatal MI) occurred in 5.2% of fenofibrate and 5.9% of placebo patients (HR.89, 95% CI , p=.16) 24% reduction in nonfatal MI (HR.76, 95% CI ) but a 22% increase in coronary death (HR 1.19, 95% CI ) total coronary events reduced with treatment in the 7,664 patients without previous CAD, 8.9% vs 1.8%, p<.1 benefit seen in patients with low HDL-C, 13.% vs 15.1%, p=.2 The Field Study Investigators, Lancet 25;366:1849 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Trial 9,795 patients with type II diabetes randomized to micronized fenofibrate 2 mg/day or to placebo and followed for 5 years total cholesterol mmol/l with either a TC/HDL-C ratio 4 or triglycerides mmol/l primary outcome (coronary death or nonfatal MI) occurred in 5.2% of fenofibrate and 5.9% of placebo patients (HR.89, 95% CI , p=.16) 24% reduction in nonfatal MI (HR.76, 95% CI ) but a 22% increase in coronary death (HR 1.19, 95% CI ) total coronary events reduced with treatment in the 7,664 patients without previous CAD, 8.9% vs 1.8%, p<.1 benefit seen in patients with low HDL-C, 13.% vs 15.1%, p=.2 The Field Study Investigators, Lancet 25;366:1849 What Are the Clinical Differences Between Gemfibrozil and Fenofibrate? fenofibrate causes fewer problems when used with a statin gemfibrozil reduced events in both the Helsinki Heart Study and the VA-HIT Trial (both primary and secondary prevention) fenofibrate failed to significantly reduce events in FIELD as-yet-unpublished data indicate that fenofibrate increased creatinine and homocysteine levels in FIELD, negating a significant event reduction CLINICAL LIMITATION: Gemfibrozil is effective, but must be used cautiously with a statin Fenofibrate is safer with a statin, but has no proven efficacy Potential Drug Therapy for Metabolic Syndrome fibrate niacin statin glitazone rimonabant antihypertensive aspirin
8 Niacin in the Coronary Drug Project 8,341 men aged 3-64 with previous MI randomized to low or high dose estrogen, dextrothyroxine, clofibrate, niacin 3 gm/day or placebo between the 2 estrogen arms and the dextrothyroxine arm were discontinued early due to excess adverse events, and clofibrate showed no benefit niacin (n=1,119) and placebo (n=2,789) patients followed for 6.2 years primary endpoint, total mortality, was 24.8% in niacin group and 25.9% in placebo group (p=ns) however, MI was significantly reduced in the niacin group (1.4% versus 14.7%) Coronary Drug Project Research Group, JAMA 1975;231:36 Niacin After the Coronary Drug Project 5 years after publication of the results, the investigators followed up the patients to assess long term adverse effects of treatment on mortality with a mean follow-up of 15 years, nearly 9 years after the end of the trial, all-cause mortality in the other drug groups were all similar to placebo but in the niacin group, mortality was reduced by 11% (52.% versus 58.2%, p=.4) the investigators estimated that only 1 of the 69 fewer deaths in the niacin group could be attributed to the lower infarction rate during the trial Canner PL et al, J Am Coll Cardiol 1986;8:1245 Niacin in Trials With Surrogate Endpoints HATS the combination of simvastatin + naicin lowered LDL-C by 42%, increased HDL-C by 26%, and halted progression of coronary disease by angiography compared to placebo over 3 years in a study of 16 patients Brown BG et al, N Engl J Med 21;345:1583 ARBITER 2 adding 1, mg of extended-release niacin to statintreated patients with CAD halted progression of carotid intima-media thickness over 12 months, while progression occurred in placebo-treated statin patients despite LDL-C of 86 mg/dl Taylor AJ et al, Circulation 24;11:3512 Change in Carotid IMT ARBITER 2: Carotid IMT Results p=.8 p<.1 p=ns Taylor AJ et al, Circulation 24;11:3512 p=.26 All Pts No DM/MS DM/MS Placebo Niacin p=ns AIM HIGH: Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes 33 patients Men and women Aged 45 years Established vascular disease and atherogenic dyslipidemia (low HDL-C and high triglycerides) Primary End Point Composite of CHD death, nonfatal MI, ischemic stroke, or hospitalization for highrisk ACS with objective evidence of ischemia Simvastatin 4 mg + ER niacin 2 g Simvastatin 4 mg 4-year follow-up Key Secondary End Points Composite of CHD death, nonfatal MI, or ischemic stroke HPS2 THRIVE: Heart Protection Study 2 Treatment of HDL to Reduce the Incidence of Vascular Events 2 patients Statin therapy Men and women to optimal Aged 5-8 years LDL-C level History of MI, stroke, or PAD ~7 patients with diabetes Coordinating centers in UK, China, and Scandinavia Primary End Point MI, stroke, revascularization procedures ER niacin+mk-524a combination tablet Placebo 4-year follow-up ER, extended release Estimated completion: 21 Estimated completion: 212
9 Potential Drug Therapy for Metabolic Syndrome fibrate niacin statin glitazone rimonabant antihypertensive aspirin Major Randomized Statin Trials in CAD Primary Prevention WOSCOPS, AFCAPS/TexCAPS Secondary Prevention - Stable CAD 4S, CARE, LIPID, TNT, IDEAL Acute Coronary Syndromes MIRACL, PROVE-IT, A to Z Populations at Risk - Heart Protection Study Hypertension: ALLHAT, ASCOT Diabetes: CARDS, ASPEN Elderly: PROSPER Stroke: SPARCL Potentially Beneficial Effects of Statins in the Metabolic Syndrome lowering LDL-C and shifting LDL particle size upward lowering high triglyceride levels minor increase in HDL-C levels improvement in endothelial dysfunction reduction in levels of inflammatory markers such as hs-crp normalization of platelet hyperaggregability Furthermore, statins have been shown to reduce events in patients with diabetes (CARDS, HPS), hypertension (ASCOT), and low HDL-C (AFCAPS/TexCAPS) AFCAPS/TexCAPS: Primary Endpoint: First Acute Major Coronary Event* Cumulative incidence Placebo Lovastatin >5 Years of follow-up 37% Risk Reduction (p<.1) Includes unstable angina, fatal and nonfatal MI and sudden cardiac death Downs JR et al, JAMA 1998;279;1615 Event rate AFCAPS/TexCAPS: Primary End Point Events by HDL-C C Tertile at Entry and by Treatment HDL-C mg/dl Downs JR et al, JAMA 1998;279:1615 Placebo Lovastatin % of patients Heart Protection Study: Major Vascular Events by HDL-C C and by Treatment < >43 HDL-C mg/dl Heart Protection Study Collaborative Group. Lancet. 22;36:7 Placebo Simvastatin
10 Major Cardiovascular Events in Patients With Metabolic Syndrome Proportion of patients experiencing major cardiovascular event* HR =.71 (95% CI.61,.84) P <.1 Atorvastatin 1 mg Atorvastatin 8 mg Relative risk reduction = 29% Time (years) *CHD death, nonfatal non procedure-related MI, resuscitated cardiac arrest, fatal or nonfatal stroke Deedwania P et al, Lancet 26;368:919 Potential Drug Therapy for Metabolic Syndrome fibrate niacin statin glitazone rimonabant antihypertensive aspirin Prevention of Diabetes by Rosiglitazone Among Subjects with Impaired Fasting Glucose or Glucose Tolerance The DREAM Trial 5269 adults with impaired fasting glucose, impaired glucose tolerance, or both, and no evidence of cardiovascular disease were randomized to placebo or rosiglitazone 8 mg/day and followed for 3 years primary endpoint was composite of death or diabetes primary endpoint occurred in 36 rosiglitazone and 686 placebo pts (11.6% vs 26.%, HR.4, 95% CI , p<.1) 133 rosiglitazone and 798 placebo pts became normoglycemic (5.5% vs 3.3%, HR 1.71, 95% CI , p<.1) heart failure developed in 14 rosiglitazone and 2 placebo patients (p=.1) Gerstein HC et al, Lancet 26;368:196 Effects of Pioglitazone on Lipoproteins, Inflammatory Markers and Adipokines in Non-Diabetic Subjects with Metabolic Syndrome 6 non-diabetic subjects with the metabolic syndrome and low HDL-C randomized to pioglitazone 3 45 mg/day or placebo for 12 weeks no change in body weight, blood glucose, insulin, or LDL-C HDL-C Small HDL particles Large HDL particles Small LDL particles Large LDL particles hs-crp HOMA-IR adiponectin Change vs Placebo +14% -16% +36% -18% +83% -31% -22% +111% p value < <.1 Effect of Rimonabant on Metabolic Risk Factors in Obese Subjects with Dyslipidemia rimonabant is a selective cannabinoid-1 receptor blocker 1,36 obese subjects with hypertriglyceridemia and high TC/HDL-C ratio randomized to placebo or rimonabant 5 or 2 mg/day and followed for 52 weeks rimonabant 2 mg/day versus placebo 6.7 Kg weight loss, 5.8 cm decrease in waist circumference, 1.% increase in HDL-C, and 13.% decrease in triglycerides (all p<.1) prevalence of metabolic syndrome decreased from 54 to 25.8% no change in LDL-C but decrease in hs-crp Després JP et al, N Engl J Med 25;353:2121 Szapary PO et al, ATVB 26;26:182
11 Effect of Rimonabant on Body Weight, Waist Circumference, Plasma Triglycerides, and HDL-Cholesterol Levels Després JP et al, N Engl J Med 25;353:2121 Age: 44 years Weight: 26 lbs Height: 5 4 BMI: 35.4 BP: 142/88 mmhg Fasting blood sugar 116 mg/dl Total C: 24 mg/dl HDL-C: 36 mg/dl Triglycerides: 42 mg/dl LDL-C: 134 mg/dl hs-crp: 2.6 mg/dl Summary metabolic syndrome is an expanding epidemic portending disastrous consequences in terms of diabetes and vascular disease the causes, excess caloric intake and lack of exercise, are cultural and environmental the optimal treatment, diet and exercise, is usually ineffective drug therapy can ameliorate components of the metabolic syndrome and reduce the risk of vascular disease and diabetes patients with metabolic syndrome present an enormous challenge to their physicians
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationAggressive Lipid Management for Diabetes
Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationMethods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationIn the Know: Canadian Guidelines for Dyslipidemia, 2003
In the Know: Canadian Guidelines for Dyslipidemia, 2003 In his reviews of Canadian dyslipidemia guidelines, Dr. Curnew explores the impact of major trials, the assessment and categories of risk, and both
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationThe Metabolic Syndrome Prof. Jean-Pierre Després
The Metabolic Syndrome 1 Jean-Pierre Després, Ph.D., FAHA, FIAS Quebec Heart and Lung Institute Department of Medicine Université Laval Québec, Canada Reaven s syndrome X Triglycerides HDL cholesterol
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None BURDEN OF CORONARY ARTERY DISEASE IN DIABETES IN INDIA Amal Kumar Banerjee MD, DM,FACC,FESC,FACP,FAPSC,FICC President Association of Physicians of India SAARC Cardiac
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationQué factores de riesgo lipídicos debemos controlar? En qué medida?
Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk
More informationContents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies
Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More information